Glyburide · DiaBeta

Small molecule

Approved / Phase 4Sulfonylurea receptor (SUR1)No featureable registry evidence
Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (12)
Type 2 Diabetes
NCT00286468 · Takeda
2006-04 – 2007-06 · Diabetes Mellitus
What this study did
NCT00255541 · AstraZeneca
2004-09 – 2006-12 · Type 2 Diabetes
What this study did
NCT00267683 · Novo Nordisk A/S
2005-12 – 2006-04 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00251940 · AstraZeneca
2004-07 – 2006-03 · Type 2 Diabetes
What this study did
NCT00759720 · Takeda
2003-11 – 2004-12 · Diabetes Mellitus
What this study did
NCT00035542 · Bristol-Myers Squibb
2001-12 – 2003-10 · Diabetes Mellitus, Non-Insulin-Dependent
What this study did
Other / comorbidity
NCT02864953 · Remedy Pharmaceuticals, Inc.
2018-08-29 – 2023-08-18 · Brain Edema, Stroke, Acute
What this study did
NCT02375828 · Assistance Publique - Hôpitaux de Paris
2015-03-20 – 2019-07-22 · Neonatal Diabetes Secondary to Mutation in the Potassium Channel
What this study did
NCT01731431 · Assistance Publique - Hôpitaux de Paris
2012-05-18 – 2017-06-02 · Diabetes, Gestational
What this study did
NCT01215331 · Université de Sherbrooke
2010-08 – 2016-05 · Gestational Diabetes Mellitus
What this study did
NCT02080377 · University of Edinburgh
2014-07 – 2016-03 · Pregnancy, Gestational Diabetes
What this study did
NCT00046462 · Sanofi
2001-11 – 2004-12 · Diabetes Mellitus
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT03284463 · Nanfang Hospital, Southern Medical University
2018-01-01 – 2023-05-28 · Acute Stroke
What this study did
NCT00515801 · University Hospital, Basel, Switzerland
started 2007-06 · Diabetes Mellitus, Type 1
What this study did
Phase 2 (6)
Type 2 Diabetes
NCT02830048 · University of Oxford
2016-07 – 2017-03-09 · Diabetes Mellitus, Type 2
What this study did
NCT00451620 · University of British Columbia
2003-11 – 2011-09 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT05687500 · Assistance Publique - Hôpitaux de Paris
2023-05-20 – 2026-01-08 · Transient; Hypoglycemia, Neonatal, Preterm, Glibenclamide Adverse Reaction
What this study did
NCT01794182 · Remedy Pharmaceuticals, Inc.
2013-06-13 – 2016-04-04 · Ischemic Stroke, Malignant Edema
What this study did
NCT01454154 · Remedy Pharmaceuticals, Inc.
2011-12-17 – 2015-02-20 · Traumatic Brain Injury
What this study did
NCT00610038 · Assistance Publique - Hôpitaux de Paris
2006-07 – 2011-12 · Diabetes Mellitus
What this study did
Phase 1/2 (5)
Other / comorbidity
NCT05148403 · Beijing Tiantan Hospital
2021-10-22 – 2022-10-01 · Traumatic Brain Injury
What this study did
NCT02460874 · University of Alabama at Birmingham
2017-08-16 – 2021-05-19 · Cerebral Edema, Brain Metastases
What this study did
NCT02524379 · Ohio State University
2017-02-14 – 2021-02-08 · Acute Spinal Cord Injury
What this study did
NCT01329016 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2011-07 – 2015-02-28 · Gestational Diabetes Mellitus
What this study did
NCT01268683 · Remedy Pharmaceuticals, Inc.
2011-05-26 – 2012-06-07 · Ischemic Stroke
What this study did
Phase 1 (19)
Type 2 Diabetes
NCT02815787 · Jiangsu HengRui Medicine Co., Ltd.
2014-03 – 2014-07 · Type 2 Diabetes
What this study did
NCT00388986 · Hoffmann-La Roche
2006-10 – 2007-07 · Diabetes Mellitus Type 2
What this study did
Other / comorbidity
NCT07221799 · University of Maryland, Baltimore
2026-09-01 – 2029-09-01 · Multiple Sclerosis, Neuropathic Pain
What this study did
NCT05426681 · Francis Farhadi
2022-07-07 – 2028-05 · Acute Spinal Cord Injury
What this study did
NCT04859452 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2021-05-26 – 2021-07-09 · Healthy Subjects
What this study did
NCT03856970 · Ironwood Pharmaceuticals, Inc.
2019-03-11 – 2019-07-03 · Healthy Volunteers
What this study did
NCT03855306 · Genuine Research Center, Egypt
2018-06-30 – 2018-08-15 · Healthy
What this study did
NCT02726490 · Texas Tech University Health Sciences Center, El Paso
2016-07 – 2018-08-14 · Gestational Diabetes
What this study did
NCT02128022 · Papworth Hospital NHS Foundation Trust
2014-07 – 2016-03 · Angina Pectoris
What this study did
NCT01716338 · Washington University School of Medicine
2013-01 – 2014-08 · Healthy Volunteers
What this study did
NCT01132703 · Biogen
2010-01-07 – 2010-05-07 · Traumatic Brain Injury, Stroke
What this study did
NCT00935363 · University of California, San Francisco
2010-02 – 2010-04 · Healthy
What this study did
NCT01733108 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-07 – 2008-09 · Healthy
What this study did
NCT02183428 · Boehringer Ingelheim
2008-05 – 2008-07 · Healthy
What this study did
NCT00865436 · Actavis Inc.
2004-04 – 2004-04 · Healthy
What this study did
NCT00836472 · Teva Pharmaceuticals USA
2003-04 – 2003-04 · Healthy
What this study did
NCT00835991 · Teva Pharmaceuticals USA
2003-02 – 2003-02 · Healthy
What this study did
NCT00864734 · Actavis Inc.
2002-11 – 2002-11 · Healthy
What this study did
NCT00865241 · Actavis Inc.
2002-11 – 2002-11 · Healthy
What this study did
Phase 4 (18)
Type 2 Diabetes
NCT03089333 · University of Campinas, Brazil
2016-07 – 2017-12 · Hypertension, Diabetes Mellitus, Type 2, Blood Pressure, Obesity, Cardiac Hypertrophy, Microalbuminuria, Vascular Stiffness
What this study did
NCT02145611 · Dr. José Fernando Vilela-Martin MD PhD
2013-07 – 2016-05 · Type 2 Diabetes Mellitus, Hypertension, Endothelial Dysfunction
What this study did
NCT01867502 · Hospital de Clinicas de Porto Alegre
2014-04 – 2015-08 · Diabetes Mellitus, Type 2, Hypoglycemic Agents, Diabetic Blood Glucose Monitoring, Exercise
What this study did
NCT01456650 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2011-03 – 2012-12 · Type 2 Diabetes
What this study did
NCT00035568 · Bristol-Myers Squibb
2002-02 – 2003-06 · Diabetes Mellitus, Non-Insulin-Dependent
What this study did
NCT01698931 · Novo Nordisk A/S
2002-04-26 – 2003-03-06 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07802561 · Nishtar Medical University
2026-04-18 – 2026-10-17 · Gestational Diabetes Mellitus (GDM)
What this study did
NCT03029702 · Maisa N. Feghali, MD
2018-02-28 – 2023-08-31 · Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes
What this study did
NCT05137678 · Beijing Tiantan Hospital
2021-10-19 – 2022-12-01 · Subarachnoid Hemorrhage
What this study did
NCT03569540 · University of Sao Paulo General Hospital
2018-07-03 – 2019-12-01 · Subarachnoid Hemorrhage, Aneurysmal
What this study did
NCT03078725 · The University of Texas Health Science Center, Houston
2017-06-20 – 2018-05-10 · Gestational Diabetes Mellitus, Class A2
What this study did
NCT02091336 · Hospital de Clinicas de Porto Alegre
2014-01 – 2016-12 · Gestational Diabetes
What this study did
NCT00744965 · University of Texas Southwestern Medical Center
2008-09-16 – 2016-01 · Mild Gestational Diabetes
What this study did
NCT01947699 · University of Pittsburgh
2013-09 – 2014-09 · Gestational Diabetes
What this study did
NCT00160485 · Tripler Army Medical Center
2004-06 – 2010-06 · Gestational Diabetes
What this study did
NCT00417729 · Taichung Veterans General Hospital
2007-01 – 2009-01 · Diabetes Mellitus
What this study did
NCT00472875 · King's College Hospital NHS Trust
started 2007-05 · Type 1 Diabetes Mellitus
What this study did
Early phase / not applicable (13)
Type 2 Diabetes
NCT00232583 · University of Texas Southwestern Medical Center
2003-11 – 2011-12 · Type 2 Diabetes Mellitus
What this study did
NCT00608179 · Vanderbilt University
2002-08 – 2010-12 · Type 2 Diabetes
What this study did
NCT00194896 · University of Washington
2000-02 – 2008-12 · Type 2 Diabetes Mellitus
What this study did
NCT00371306 · Regional Obstetrical Consultants
2002-09 – 2008-09 · Gestational Diabetes, Type 2 Diabetes, Pregnancy
What this study did
NCT00549874 · University of Michigan
2002-02 – 2006-11 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT06589141 · Assiut University
2025-01-01 – 2026-06-30 · Gestational Diabetes Mellitus in Pregnancy
What this study did
NCT03886922 · Danish Headache Center
2019-04-01 – 2023-08-30 · Hemodynamics of Cranial Arteries, Headache, Cerebral Blood Flow
What this study did
NCT00965991 · University of New Mexico
2003-07 – 2023-08 · Gestational Diabetes
What this study did
NCT04960657 · Danish Headache Center
2020-10-20 – 2021-03-19 · Migraine, Headache, Pain
What this study did
NCT03741530 · Xijing Hospital
2018-12-15 – 2020-09-23 · Intracerebral Hemorrhage
What this study did
NCT04231617 · Danish Headache Center
2020-01-20 – 2020-09-01 · Hemodynamics of Cranial Arteries, Headache, Cerebral Blood Flow
What this study did
NCT02255006 · Kyunghee University Medical Center
2014-05 – 2014-12 · Healthy
What this study did
NCT00696982 · Assaf-Harofeh Medical Center
2008-06 – 2009-06 · Diabetes Mellitus, Arterial Stiffness
What this study did
Used as active comparator (18)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Type 2 Diabetes
NCT05688332 · University of Zambia
2023-08 – 2024-01 · Diabetes Mellitus Type 2 Without Complication
What this study did
NCT01822548 · Azienda Ospedaliero-Universitaria di Parma
2010-10 – 2015-01 · Type 2 Diabetes
What this study did
NCT00393718 · Novo Nordisk A/S
2006-11 – 2008-05 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00279045 · GlaxoSmithKline
2000-01-03 – 2006-06-19 · Diabetes Mellitus, Type 2
What this study did
NCT00521820 · Takeda
2000-06 – 2003-10 · Diabetes Mellitus
What this study did
NCT00521742 · Takeda
2001-03 – 2003-01 · Diabetes Mellitus
What this study did
Phase 2 (1)
Type 2 Diabetes
NCT01029795 · Eli Lilly and Company
2010-02 – 2010-06 · Diabetes Mellitus, Type 2
What this study did
Phase 1/2 (1)
Type 2 Diabetes
NCT01145534 · Federal University of Paraíba
2009-01 – 2009-10 · Diabetes
What this study did
Phase 1 (1)
Type 2 Diabetes
NCT01319734 · Al-Neelain University
2011-02 – 2015-12 · Type 2 Diabetes Mellitus
What this study did
Phase 4 (9)
Type 2 Diabetes
NCT01107717 · The University of Texas Health Science Center at San Antonio
2009-01 – 2023-02-03 · Diabetes
What this study did
NCT02919345 · University of Campinas, Brazil
2017-01 – 2019-03 · Diabetes Mellitus, Type 2, Coronary Artery Disease, Carotid Artery Diseases
What this study did
NCT02318693 · Merck Sharp & Dohme LLC
2015-02-04 – 2015-12-15 · Type 2 Diabetes Mellitus
What this study did
NCT00770835 · Takeda
2009-03 – 2011-05 · Diabetes Mellitus
What this study did
NCT00347100 · Sanofi
2006-06 – 2008-05 · Diabetes Mellitus, Type 2
What this study did
NCT00123643 · St. Paul Heart Clinic
2003-05 – 2005-12 · Type 2 Diabetes Mellitus
What this study did
NCT01605773 · Novo Nordisk A/S
2001-11-08 – 2003-03-13 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT02201602 · Khoo Teck Puat Hospital
2014-08 – 2016-07 · Diabetes
What this study did
NCT00494312 · Takeda
2000-10 – 2005-06 · Diabetes Mellitus, Liver
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Type 2 Diabetes
NCT00313313 · AstraZeneca
2006-04 – 2008-09 · Diabetes
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Glyburide (DiaBeta): this drugApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 88 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow DiaBeta (Glyburide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
May 2027 (1)
Phase 1Acute Spinal Cord InjuryRecruiting
Est. primary completion 2027-05 · NCT05426681 · CT.gov ↗
What to watch
2028 (1)
September 2028 (1)
Phase 1Multiple Sclerosis, Neuropathic PainNot yet recruiting
Est. primary completion 2028-09-01 · NCT07221799 · CT.gov ↗
What to watch

See the full readout calendar ↗